January 2, 2025 7:19am
Not a technical indicator -- “hope” that momentum regains its propulsion
Happy New Year – 2025
There is no breadline for share pricing and fact-based intelligence! A daily analytic read-out from RMi is constructed of signals thought-provoking share pricing situations.
Pre-open Indications: 7 Positive and 1 Negative Indications
Never leave an investor uninform
Remember that overnight and pre-open actions’ futures and markets doesn’t necessarily translate into actual trading in today’s market session.
My interpretation of the morning’s numbers is written to be informative; it’s built on what happened or will happen behind the headline today!
Tuesday’s night’s … RegMed Investors (RMi) Closing Bell: lordy, lordy, thanks from above, we’ve had enough … https://www.regmedinvestors.com/articles/13751
Wednesday was a holiday – New Years
Thursday; the pre-open Dow futures are UP +0.74% or (+316 points), the S&P futures are UP +0.86% or (+51 points) and the Nasdaq futures are UP +1.08% or (+227 points)
- Stock futures were trending higher,
- European markets were off to a positive start.
- Asian stocks traded mixed
Henry’omics: We need to more than consider the economic environment to comprehend the micro re “our” universe of cell and gene therapy companies
Even though, stocks fell in weak trading in the last week of 2024, the year still produced solid returns.
- The S&P 500 surged +23% last year, while the Dow added +13%, the Nasdaq outpaced with a +29% advance, thanks to AI and Interest rates
Tuesday: The Dow closed DOWN -29.51 points or -0.07%, the S&P closed DOWN -25.31 points or -0.43% while the Nasdaq closed DOWN -175.89 points or -0.90%
- Monday: The Dow closed DOWN -418.48 points or -0.97%, the S&P closed DOWN -63.90 points or -1.07% while the Nasdaq closed DOWN -235.25 points or -1.19%
Tuesday’s advance/decline line ended with a barely positive close at the close of 16 incliner, 15 decliners and 4 flats
- Monday’s advance/decline line ended with a negative close at the close of 7 incliner, 27 decliners and 1 flat
Economic Data Docket: weekly jobless claims
Q4/24: January 2025 – 1st session and 1 holiday
Q4/24:
- December 1 holiday, 15 negative and 5 positive closes
- November 10 negative and 9 positive closes
- October: 8 positive and 15 negative closes
Companies in my headlights – It’s your decision; I provide ideas and context
I post about “indication intelligence” looking toward investment conferences … to assist investors with insight into sector vulnerabilities and strengths. A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a
Recommendation, or grounds for inferring or a basis for believing.
Positive Indications:
Blueprint Medicine (BPMC) closed up +$0.40 and shows a pre-open positive of +$0.32 or +0.37%
BioLife Solutions (BLFS) closed down -$0.31 and shows a pre-open positive of +$0.38 or +1.46%
Mesoblast (MESO closed down -$1,24 with a positive +$0.05 or +0.;25% aftermarket
Prime Medicine (PRME) closed up +$0.14 and shows a pre-open positive of +$0.13 or +4.45%
Vericel (VCEL) closed down -$0.39 and shows a pre-open positive of +$1.08 or +1.97%
Voyager Therapeutics (BYGR) closed up -$0.,06-8 with a positive +0.37 or +6.63% aftermarket
uniQure NV (QURE) closed up +$0.04 and shows a pre-open positive of +$0.04 or +5.23%
Negative Indications:
Alnylam Pharmaceuticals (ALNY) closed down -0.70 and shows a pre-open negative of -$2.01 or -0.85%
The BOTTOM LINE: like I wrote, New Year, new expectations …
- The 2024's year-end dip 'creates … SOME buying opportunity!
- However, earnings from Q4/24 are due …
Some believe that "pragmatic optimism" will "set the tone for 2025," outlining that they expects "a return to normal volatility" and "an average year for stocks." He adds that his market outlook for the new year is high single-digit returns from the S&P 500. He suggests the good news may already be priced in. < ADAM Turnquist, LPL Financial chief technical strategist>
Big Point to remember “Think about it; the biggest problem the cell and gene therapy sector has … 99% of them have no earnings! If rates are higher for longer, that means that sector companies will continue to struggle or be unable to raise capital and therefore be subject to debt servicing firms!” <Me>
- 2024 saw some life return to the IPO (initial public offering) market, which saw companies deterred and struggle to go public since the COVID-19 pandemic.
What could 2025, and even 2026, have in store for the capital access space ?
"You'll see a number of cell and gene therapy comandantes drive for secondaries – they’re desperate for cash, but I do think a lot of cell and gene therapy sector companies NEED to be focused on what is driving their own growth —they're focused on a lot of change BUT … that's happening in the market… capital expansion is second.
Partners are the gift of life
I seem to be asking a question followed by a question …
- Do we need to brace ourself for more economics and their down trending affect?
- Is this market STILL “bubblicious” my concerns are macroeconomic and valuation
Welcome to my world of defining the “grey’ in our universe!
- The sector is what it is, until it isn’t and even then, it doesn’t seem to be… as NOT much changes as the sector’s share pricing rides the waves of volatility, algorithms, electronic trading and short covering.
- I am more frequently right than consequentially wrong; if I wanted to be liked, I wouldn’t have been an analyst/journalist.
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives. Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.
Henry McCusker, the editor and publisher of RegMed Investors could hold or have positions securities referred to in this publication and he will NOTIFY investors of holdings.
